Cyclic diarylboron derivatives as NLRP3 inflammasome inhibitors

University of Manchester 2020. Cyclic diarylboron derivatives as NLRP3 inflammasome inhibitors. US 10570157. [Patent].

Preview

PDF - Published Version Download (4MB) | Preview

Abstract

Inhibitor compounds are disclosed. The compounds are effective in the treatment of diseases or conditions in which interleukin 1 .beta. activity is implicated. Methods of synthesis of the compounds, as well as pharmaceutical compositions comprising the compounds are also disclosed.

Item Type:	Patent
Date Type:	Published Online
Status:	Published
Schools:	Biosciences
Publisher:	US Patent
Date of First Compliant Deposit:	18 May 2020
Date of Acceptance:	25 February 2020
Last Modified:	07 Nov 2022 10:17
URI:	https://orca.cardiff.ac.uk/id/eprint/131765

Actions (repository staff only)

Edit Item